Skip to main content
. 2002 Aug 6;4(5):307–321. doi: 10.1186/ar592

Table 3.

Anti-TNF therapy in ankylosing spondylitis – open questions

Long-term efficacy?
Arrest of progression of ankylosis?
Differing responses in different targets?
Dosage?
Intervals?
Continous or intermittent therapy?
Individualization of treatment?
Long-term safety?
Repeated screening for autoantibodies?
Adding of DMARDs to suppress antibody formation?
Duration of tuberculosis prophylaxis?